A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma

Molecular Oncology 2017 November 1 [Epub ahead of print] [Link] Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF…

Read More

Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition

Clinical Cancer Research 2017 October [Epub ahead of print] [Link] Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld JS, Iorio F, Kolluri KK, Garnett MJ, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C Abstract PURPOSE: Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage.…

Read More

Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma

Oncotarget 2017 April [Epub ahead of print] [Link] Satoh T, Tatsuta T, Sugawara S, Hara A, Hosono M Abstract Malignant mesothelioma is an aggressive cancer with limited therapeutic options. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a multifunctional protein with anti-cancer activity. The effects of pemetrexed, cisplatin, and cSBL were evaluated in…

Read More

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines

Genes & Cancer 2017 January [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28435517″>Link] Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S Abstract Malignant pleural mesothelioma (MPM) is a cancer of the pleural…

Read More

A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.

Journal of Thoracic Oncology 2017 April [Epub ahead of print] [Link] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E Abstract INTRODUCTION: BRCA1-associated protein-1, BAP1, is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A and DNA repair. BAP1 mutations are…

Read More

Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell

International Journal of Biological Sciences 2016 October [Link] Sohn EJ, Won G, Lee J, Yoon SW, Lee I, Kim HJ, Kim SH Abstract Malignant pleural mesothelioma (MPN), which is caused by asbestos exposure, is one of aggressive lung tumors. In the present study, we elucidated the anti-tumor mechanism of ursolic acid in malignant mesotheliomas. Ursolic…

Read More

Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis

Pathology Oncology Research 2017 January 4 [Epub ahead of print] [Link] Plönes T, Fischer M, Höhne K, Sato H, Müller-Quernheim J, Zissel G Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that arises from the surface of the pleura and is associated with a history of asbestos exposure. The tumor is characterized by…

Read More